DEPARTMENTS: Pharmacology Consult

Food and Drug Administration Accelerated Approval of Lecanemab for Early Alzheimer's Disease—Hope, Reality, and the Unknown Going Forward

O'Malley, Patricia Anne PhD, APRN-CNS

Author Affiliation: Premier Health—Miami Valley Hospital, Dayton, Ohio.

The author reports no conflicts of interest.

Correspondence: Patricia Anne O'Malley, PhD, APRN-CNS, Premier Health- Nursing Research, 1 Wyoming Street, Dayton, OH 45409 ([email protected]; [email protected]).

Clinical Nurse Specialist 37(3):p 111-113, 5/6 2023. | DOI: 10.1097/NUR.0000000000000745

Buy
CME Test

Full Text Access for Subscribers:

Individual Subscribers

Institutional Users

Access through Ovid^®

Not a Subscriber?

Buy

Request Permissions

You can read the full text of this article if you:

Access through Ovid

Secondary Logo

Journal Logo

Food and Drug Administration Accelerated Approval of Lecanemab for Early Alzheimer's Disease—Hope, Reality, and the Unknown Going Forward

Full Text Access for Subscribers:

Institutional Users

Not a Subscriber?

Article Level Metrics

Related Links

Related Videos

Readers Of this Article Also Read

Food and Drug Administration Accelerated Approval of Lecanemab for Early Alzheimer's Disease—Hope, Reality, and the Unknown Going Forward : Clinical Nurse Specialist

Full Text Access for Subscribers:

Individual Subscribers

Institutional Users

Not a Subscriber?